Abstract: Objective  To explore the expression levels of hsa-miR-23a and hsa-miR-566 in patients with newly diffuse large B cell lymphoma(DLBCL) and their clinical significance.
  Methods  Sixty cases of newly DLBCL patients were selected as the observation group, and 60 cases of healthy people as the control group. The expression levels of hsa-mir-23a and hsa-mir-566 in peripheral blood of the two groups were detected and compared. The relationship between the expression level of hsa-mir-23a and hsa-mir-566 and the clinical characteristics and prognosis of DLBCL were analyzed.
  Results  The expression levels of sa-mir-23a-3p and hsa-mir-566 in the observation group were higher than those in the control group, The difference was statistically significant(P＜0.05). The expression levels of hsa-miR-23a-3p and hsa-miR-566 in peripheral blood were related to tumor stage, number of lymph node metastasis, and international prognostic index(IPI) points(all P＜0.05). The mean expression levels of hsa-mir-23a-3p and hsa-mir-566 in peripheral blood of DLBCL patients were 3.35 and 1.69 as critical values. The patients were divided into hsa-mir-23a-3p high expression group(32 cases), hsa-mir-23a-3p low expression group(28 cases), hsa-mir-566 high expression group(29 cases) and hsa-mir-566 low expression group(31 cases). The overall survival rate of hsa-mir-23a-3p high expression group was 40.63%(13/32), which was significantly lower than 67.86%(19/28) of low expression group, The difference was statistically significant(χ2=4.450, P=0.035)； The median survival time of hsa-mir-23a-3p high expression group and hsa-mir-23a-3p low expression group were(26.73 months vs 32.52 months, P＜0.01). The overall survival rate of hsa-mir-566 high expression group was 37.93%(11/29), which was significantly lower than 67.74%(21/31) of low expression group. The difference was statistically significant(χ2=5.350, P=0.021). The median survival time of hsa-mir-566 high expression group and hsa-mir-566 low expression group were(27.45 months vs 32.35 months，P＜0.01).
  Conclusion  The expression of hsa-mir-23a-3p and hsa-mir-566 in the peripheral blood of patients with newly DLBCL is high, which is closely related to the clinical stage, the number of lymph node metastasis, IPI index and prognosis of patients with DLBCL, and is expected to become an important marker in the diagnosis of DLBCL.

Key words: lymphoma, B-cell, antineoplastic combined chemotherapy protocols, prognosis